ArticleAmerican journal of cancer research2026
Clinical characteristics and prognostic analysis of patients with connective tissue disease complicated by non-small cell lung cancer.
Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo summarize the clinical features, treatment patterns and survival outcomes of patients with non-small cell lung cancer (NSCLC) combined with connective tissue disease (CTD), and to determine whether CTD independently influences prognosis and treatment-related toxicity in this special patient population.
methodsIn this retrospective study, we enrolled 200 consecutive patients with pathologically confirmed NSCLC. Among them, 95 patients met the diagnostic criteria for CTD were set as the CTD group, and the remaining 105 patients with simple NSCLC as the control group. The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS), baseline tumor characteristics, metastatic patterns, first-line treatment patterns and delivery, and treatment-related adverse events (AEs). We adopted Kaplan-Meier method for survival analysis and Cox proportional hazards regression model for prognostic analysis. Prespecified subgroup analyses were performed to evaluate the prognostic effect of CTD and identify independent survival predictors.
resultsThe CTD group presented more severe intrathoracic tumor dissemination, including higher incidence of bilateral pulmonary lesions (P = 0.042) and pleural effusion (P = 0.011). Compared with controls, the CTD group were less likely to receive platinum-based doublet chemotherapy (P = 0.035), cisplatin-based chemotherapy (P = 0.017), immune checkpoint inhibitor (ICI)-containing therapy (P = 0.009) and thoracic radiotherapy (P = 0.029). Meanwhile, the CTD group had higher risks of chemotherapy dose reduction (P = 0.011), treatment delay longer than 7 days (P = 0.015) and early treatment discontinuation (P = 0.002). In survival outcomes, the median PFS was 5.4 vs 7.8 months (HR, 1.58; 95% CI, 1.17-2.13; P = 0.003), and the median OS was 9.7 vs 14.6 months (HR, 1.76; 95% CI, 1.29-2.40; P<0.001). The incidence of grade 3-4 treatment-related AEs was significantly higher in the CTD group (P = 0.010). Multivariate regression analysis confirmed that CTD was an independent adverse prognostic factor for poor OS (HR, 1.41; 95% CI, 1.01-1.97; P = 0.044).
conclusionFor patients diagnosed with NSCLC, comorbid CTD is correlated with aggravated intrathoracic tumor dissemination, reduced treatment intensity and treatment tolerance, increased severe toxicity, and dismal long-term survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.